Patent · US Active

Agent for evading immune response

US9387175B2 · kind B2 · utility

2Cited by
2References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 3, 2012
Grant dateJul 12, 2016
Priority date
Expiry dateDec 23, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC01P2006/12
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

It has been found that modification of surfaces of nanoparticles with a RolA protein decreases an immunostimulation activity of the nanoparticles on myeloid dendritic cells and also decreases phagocytosis of the nanoparticles by macrophages. The present invention provides nanoparticles being modified with a biological molecule and having an immune-response evasion function.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.